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Objectives
To investigate whether serial prostate magnetic resonance
imaging (MRI) may guide the utility of repeat targeted (TBx)
and systematic biopsy (SBx) when monitoring men with low-
risk prostate cancer (PCa) at 1-year of active surveillance
(AS).
Patients and Methods
We retrospectively included 111 consecutive men with low-
risk (International Society of Urological Pathology [ISUP]
Grade 1) PCa, who received protocolled repeat MRI with or
without TBx and repeat SBx at 1-year of AS. TBx was
performed in Prostate Imaging-Reporting and Data System
(PI-RADS) score ≥3 lesions (MRI-positive men). Upgrading
defined as ISUP Grade ≥2 PCa (I), Grade ≥2 with cribriform
growth/intraductal carcinoma PCa (II), and Grade ≥3 PCa
(III) was investigated. Upgrading detected by TBx only (not
by SBx) and SBx only (not by TBx) was investigated in MRI-
positive and -negative men, and related to radiological
progression on MRI (Prostate Cancer Radiological Estimation
of Change in Sequential Evaluation [PRECISE] score).
Results
Overall upgrading (I) was 32% (35/111). Upgrading in MRI-
positive and -negative men was 48% (30/63) and 10% (5/48)
(P < 0.001), respectively. In MRI-positive men, there was
upgrading in 23% (seven of 30) by TBx only and in 33% (10/
30) by SBx only. Radiological progression (PRECISE score 4–
5) in MRI-positive men was seen in 27% (17/63). Upgrading
(I) occurred in 41% (seven of 17) of these MRI-positive men,
while this was 50% (23/46) in MRI-positive men without
radiological progression (PRECISE score 1–3) (P = 0.534).
Overall upgrading (II) was 15% (17/111). Upgrading in MRI-
positive and -negative men was 22% (14/63) and 6% (three of
48) (P = 0.021), respectively. In MRI-positive men, there was
upgrading in three of 14 by TBx only and in seven of 14 by
SBx only. Overall upgrading (III) occurred in 5% (five of
111). Upgrading in MRI-positive and -negative men was 6%
(four of 63) and 2% (one of 48) (P = 0.283), respectively. In
MRI-positive men, there was upgrading in one of four by
TBx only and in two of four by SBx only.
Conclusion
Upgrading is significantly lower in MRI-negative compared to
MRI-positive men with low-risk PCa at 1-year of AS. In serial
MRI-negative men, the added value of repeat SBx at 1-year
surveillance is limited and should be balanced individually
against the harms. In serial MRI-positive men, the added
value of repeat SBx is substantial. Based on this cohort, SBx is
recommended to be performed in combination with TBx in
all MRI-positive men at 1-year of AS, also when there is no
radiological progression.
Keywords
low-risk prostate cancer, active surveillance, prostate MRI, PI-
RADS, PRECISE, upgrading, #ProstateCancer, #PCSM
Introduction
Active surveillance (AS) is a widely used strategy for
managing men with low-risk prostate cancer (PCa) to reduce
overtreatment and treatment-related side-effects, with
confirmed oncological safety at long-term follow-up [1]. The
fear of under grading at time of diagnostic biopsy has led to
the development of AS protocols with strict criteria for
inclusion and monitoring, like the Prostate cancer Research
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International Active Surveillance (PRIAS) study (www.prias-
project.org) [2].
Today, MRI and targeted biopsy (TBx) are increasingly used
in the evaluation of patients with low-risk PCa who initially
opt for AS, based on systematic TRUS-guided prostate biopsy
(SBx) findings [3]. The additional use of a first pre-biopsy
MRI and subsequent TBx in these men can aid in the
exclusion of higher risk men with International Society of
Urological Pathology (ISUP) Grade ≥2 PCa, irrespective of
the timing of the MRI during follow-up (i.e., at baseline,
confirmatory or surveillance biopsy) [4-9]. A first pre-biopsy
MRI in the evaluation of men on AS for low-risk PCa has
therefore recently been adopted in the European Association
of Urology (EAU) PCa guidelines [10].
An MRI-based monitoring strategy in men with low-risk PCa on
AS is attractive to health systems and patients, potentially
avoiding a prostate biopsy procedure with its attendant
morbidities as much as reasonably possible. The Prostate Cancer
Radiological Estimation of Change in Sequential Evaluation
(PRECISE) criteria could help to qualify radiological risk of
progression on serial prostate MRI [11,12]. However, the role of
MRI in monitoring and its potential to guide the indication for
repeat biopsies (i.e., confirmatory and surveillance biopsies)
during AS is still unclear. Unanswered issues in clinical practice
are whether SBx could be omitted in cases of a negative follow-
up MRI, whether only TBx should be performed in cases of a
positive follow-up MRI, and whether biopsies should only be
performed in cases of radiological disease progression on follow-
up MRI. Recent studies provide contradictory findings in men
on AS for low-risk PCa as to whether or not serial MRI could
obviate the need for repeat biopsies [13-24]. Hamoen et al. [18]
showed an overall added value for repeat (confirmatory) SBx at
1-year of AS of 42% as compared to 7% added value for serial
MRI with or without TBx (MRI  TBx). However, Thurtle et al.
[19,20] and Elkjaer et al. [19,20] found much more added value
for serial MRI  TBx (30–50%), and less added value for repeat
SBx (9–12%) in their cohorts. Substantial evidence on
implementing prostate MRI as a monitoring tool in men on AS
for low-risk PCa is still lacking.
As virtually all AS protocols advise a repeat biopsy procedure
after 1 year on AS, we aimed to determine the potential
guidance of serial prostate MRI (i.e., positive or negative
MRI, with or without radiological progression) in the utility
of repeat TBx and SBx in men with low-risk PCa at 1-year of
AS, using different definitions for clinically significant PCa
(csPCa) as outcome measures.
Patients and Methods
Study Population
This retrospective study was approved by our Institutional
Review Board (IRB; NL45884.078.13/A301321), and written
informed consent with guarantee of confidentiality was
obtained from all study participants. No additional data other
than already collected as part of this IRB-approved study was
sought for the analyses done in this study. Men with low-risk
PCa (ISUP Grade 1) were prospectively enrolled in our in-
house clinical database as part of our AS protocol. All men
were followed according to the MRI-PRIAS study protocol
(www.prias-project.org). In summary, they underwent an
MRI  TBx at baseline (3 months after the detection of low-
risk PCa on diagnostic SBx), and during every repeat SBx
scheduled at 1 year (confirmatory biopsy), and 4, 7 and
10 years (surveillance biopsy) after diagnosis (Fig. 1). The
only upgrading or re-classification criterion was the presence
of ISUP Grade 2 (Gleason score 3 + 4) and higher PCa at
biopsy.
From November 2013 to May 2019, 517 consecutive men on
AS for ISUP Grade 1 PCa underwent at least one prostate
MRI during follow-up. At the time of analysis, 252 men had
undergone an MRI  TBx at baseline. Results of part of this
cohort have been previously published [8,9]. In all, 70/252
(28%) men had upgrading after their first MRI-TBx and
therefore ceased AS, and 71/252 (28%) men had not yet
undergone a second MRI  TBx at the time of analysis. In
the present study, we included 111 men on AS for low-risk
PCa who had undergone both a MRI  TBx at baseline and
at the time of the scheduled confirmatory SBx 1 year after
initiation of AS (Fig. 1).
Multiparametric MRI
Multiparametric MRI (mpMRI) at both time points was
performed on a 3.0-T MR scanner (Discovery MR750;
General Electric Healthcare, Chicago, IL, USA) with a 32-
channel pelvic phased-array coil. The institutional MRI
protocol included T2-weighted imaging, diffusion-weighted
imaging with apparent diffusion coefficient reconstructions,
and dynamic contrast enhanced imaging, according to the
Prostate Imaging-Reporting and Data System (PI-RADS)
version 1 and 2 guidelines [25]. All MRIs were reviewed by
one urogenital radiologist with >7 years’ experience of
prostate MRI. Individual lesions were scored according to the
PI-RADS 5-point likelihood scale for csPCa, and the index
lesions were annotated and delineated [25]. Visible MRI
lesions with a PI-RADS score of 3–5 were defined as
suspicious.
Serial MRI scans were all compared to the initial imaging
by the reporting radiologist according to the PRECISE
criteria [11,12]. The PRECISE recommendations use a 5-
point likelihood scale to qualify radiological progression on
MRI in men on AS with serial prostate MRIs. PRECISE
score 1–2 corresponds to resolution/regression of previous
features suspicious on MRI (based on a decreased
radiological size/stage/conspicuity/PI-RADS score), PRECISE
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score 3 corresponds to radiological stable disease, and
PRECISE score 4–5 to disease progression on MRI
(based on an increased radiological size/stage/conspicuity/
PI-RADS score). In clinical practice, a positive serial MRI
without radiological progression is defined as PRECISE
score 1–3.
MRI-Tbx and SBx
Biopsies were performed in a separate session. All men with a
positive (serial) MRI underwent TBx. An MRI-ultrasound
fusion system (UroStationTM, Koelis, France) was used to take
TBx of all suspicious lesions identified on MRI. The
suspicious MRI lesions, delineated on Digital Imaging and
Communications in Medicine (DICOM) images, were
targeted with 2–5 cores/lesion. An additional SBx (8–
12 cores, depending on the prostate volume) was taken in all
men at the time of confirmatory biopsy and was not blinded
from MRI results. The biopsy procedures were performed by
four experienced operators.
Pathological Review of Biopsy Specimens
One expert uropathologist reviewed all biopsy specimens
according to the ISUP 2014 modified Gleason score/Grade
Group system [26]. The presence of an invasive cribriform
growth pattern (CR) and/or intraductal carcinoma (IDC) was
routinely recorded. Upgrading, and thereby the
recommendation to switch to active treatment, was defined in
clinical practice as any ISUP Grade ≥2 PCa found by MRI 
TBx and/or SBx.
Study Endpoints
We compared the percentage of upgrading of ISUP Grade 1
PCa to csPCa between the results of MRI  TBx and SBx in
MRI-positive and -negative men on AS at the time of
confirmatory biopsy (1-year surveillance). In addition, we
assessed the percentage of upgrading related to the PRECISE
score (i.e., regressive, stable and progressive features on
prostate MRI). The percentage of upgrading was calculated
using three different definitions of csPCa: definition I, ISUP
Grade ≥2 PCa; definition II, ISUP Grade ≥2 with CR and/or
IDC PCa; and definition III, ISUP Grade ≥3 PCa.
Primary outcomes are:
1. Upgrading (definition I) in MRI-positive and -negative
men.
2. Upgrading (definition I) related to the radiological changes
between first and second MRI (PRECISE score), in MRI-
positive and -negative men.
Secondary outcome is:
1. Upgrading based on higher thresholds (definitions II and
III) for csPCa.
Statistical Analysis
Descriptive statistics were used to report the clinical patient
characteristics and percentages of upgrading. Statistically
significant differences in continuous non-parametric data
were assessed with the Mann–Whitney U-test and Wilcoxon
signed-rank test. The chi-square test for trend, McNemar test
252
t ~ 0 (3 months)
- baseline MRI ±
TBx
517
eligible for AS on 
SBx findings
108
neg. MRI
144
pos. MRI
TBx
74 70
upgradingno upgrading
t ~ 1 year
- confirmatory SBx
and 2 nd MRI ± TBx 111
71
265
no baseline MRI 
at time of 
analysis
not yet 2nd MRI 
at time of 
analysis
Included Excluded
Timeline
no TBx
Fig. 1 Flowchart of patients included in this study. AS, active surveillance; SBx, systematic biopsy; TBx, targeted biopsy.
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and Wilcoxon signed-rank test were used to test for
differences in categorical data. In accordance with the
Standards of reporting for MRI-TBx studies (START)
recommendations, cross-tabulation of the confirmatory biopsy
outcomes was performed to compare the percentage of
upgrading detected by MRI  TBx vs SBx [27]. Analyses
were performed using the Statistical Package for the Social
Sciences (SPSS), version 24.0 (SPSS Inc., IBM Corp.,
Armonk, NY, USA), with a two-tailed level of significance set
at P < 0.05.
Results
Patients’ Characteristics
The clinical patients’ characteristics with subsequent low-risk
PCa profiles did not show significant differences (except for
age) at baseline and at confirmatory biopsy at 1-year of AS
(Table 1).
Upgrading (Definition I) at 1-year Surveillance, in
MRI-Positive and -Negative Men
At 1-year surveillance, 57% (63/111) of men had a positive
follow-up MRI and 43% (48/111) had a negative follow-up
MRI. Overall, upgrading (definition I) occurred in 32% (35/
111, 95% CI 23–41), as a result of TBx and/or SBx (Table 2).
Upgrading in MRI-positive and -negative men was 48% (30/
63, 95% CI 35–61) and 10% (five of 48, 95% CI 4–23)
(P < 0.001, 95% CI for the difference 21–51), respectively. In
MRI-positive men, upgrading was 23% (seven of 30) by TBx
only, 33% (10/30) by SBx only, and 43% (13/30) by both TBx
and SBx (Table S1 for cross-tabulation of biopsy data).
In a total of 23 MRI-positive men, SBx detected upgrading.
43% (10/23, 95% CI 23–66) of the detected upgrading by SBx
in these men was (also) located on the contralateral side of
the suspicious MRI lesion(s). The overall upgrading in MRI-
positive men increased with the PI-RADS score from 38%
(five of 13, 95% CI 14–68) in PI-RADS score 3, 48% (19/40,
95% CI 32–64) in PI-RADS score 4, 60% (six of 10, 95% CI
26–88) in PI-RADS score 5 MRIs. Based on TBx results no
correlation was found for upgrading related to higher PI-
RADS score.
Upgrading (Definition I) at 1-year Surveillance,
Related to Changes on MRI in MRI-Positive and -
Negative Men
Radiological progression (PRECISE score 4–5, i.e., from non-
suspicious to suspicious and suspicious to more suspicious) in
MRI-positive men was observed in 27% (17/63). Upgrading
(definition I) in these men was 41% (seven of 17, 95% CI 18–
67), as a result of TBx and/or SBx. Upgrading occurred in
three of seven by TBx only and in three of seven by SBx only
(Table 3). No radiological progression (PRECISE score 1–3)
in MRI-positive men occurred in 73% (46/63). Upgrading in
these men was 50% (23/46, 95% CI 35–65), found by TBx
and/or SBx. Upgrading was 17% (four of 23) by TBx only
and 30% (seven of 23) by SBx only.
PRECISE score 3 (i.e., stable radiological features) in MRI-
negative men was observed in 88% (42/48), in whom
upgrading occurred in 10% (four of 42, 95% CI 3–23)
(Table 3). Radiological regression from suspicious to non-
suspicious findings (PRECISE score 1–2) in follow-up MRI-
negative men was observed in 13% (six of 48), in whom
upgrading occurred in 17% (one of six, 95% CI 1–64).
Upgrading at 1-year Surveillance, Based on Higher
Thresholds (Definitions II and III) for csPCa
Overall upgrading (definition II) was 15% (17/111, 95% CI 9–
23). Upgrading in MRI-positive and -negative men was 22%
(14/63, 95% CI 13–35) and 6% (three of 48, 95% CI 1–17)
(P = 0.021, 95% CI for the difference 2–28), respectively. In
MRI-positive men, there was upgrading in three of 14 by TBx
only, and in four of 14 by SBx only (Table 2). Related to
PRECISE, upgrading was 18% (three of 17, 95% CI 4–43) for
PRECISE score 4–5 and 15% (14/94, 95% CI 8–24) for
PRECISE score 1–3 (Table 3).
Overall upgrading (definition III) was 5% (five of 111, 95%
CI 2–10). Upgrading in MRI-positive and -negative men was
6% (four of 63, 95% CI 2–16) and 2% (one of 48, 95% CI 1–
11) (P = 0.283, 95% CI for the difference 5 to 13),
respectively. In MRI-positive men, there was upgrading in
one of four by TBx only, and in two of four by SBx only
(Table 2). Related to PRECISE, upgrading was 6% (one of 17,
95% CI 1–29) for PRECISE score 4–5 and 4% (four of 94,
95% CI 1–11) for PRECISE score 1–3 (Table 3).
Discussion
The guidance of serial prostate MRI in the utility of repeat
biopsies, when monitoring low-risk PCa men on AS, has not
been clearly established. In our clinical practice of men with
low-risk PCa on AS with subsequent MRI at baseline and at
1-year follow-up, overall upgrading from low- to
intermediate/high-risk PCa (definition I) at 1-year
surveillance was 32%. Upgrading was significantly lower in
MRI-negative men (10%) compared to MRI-positive men
(48%). In MRI-positive men, SBx detected a substantial
additional proportion of upgrading not detected by TBx;
almost half detected on the contralateral side of the
suspicious MRI lesion(s). Upgrading was similar in MRI-
positive men with radiological progression and without
radiological progression. In these two groups the additional
value of SBx in upgrading to ISUP Grade ≥2 PCa was 43%
and 30%, respectively. This argues for additional repeat SBx
4
© 2020The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Osses et al.
in men with and without radiological progression on positive
MRI. The other studied thresholds for upgrading ([definition
II] ISUP Grade ≥2 with CR and/or IDC PCa, and [definition
III] ISUP Grade ≥3 PCa) resulted in a lower overall
upgrading (15% and 5%, respectively). At these thresholds,
similar results were found with only limited upgrading in
MRI-negative men and substantial added value of SBx in
MRI-positive men. These results suggest that in serial MRI-
negative men with low-risk PCa, repeat SBx at 1-year
surveillance should be balanced against the harms on an
individual basis. The risk of missing a timely diagnosis of
high-risk PCa is low. However, in serial MRI-positive men
repeat SBx combined with TBx should be performed in all
MRI-positive low-risk PCa men at 1-year surveillance to gain
maximal diagnostic precision. This strategy could save a
repeat biopsy procedure at 1-year follow-up in 43% of men at
the cost of missing 2–10% of csPCa (depending on the
threshold used) in our population.
Two important clinical implications from our present results
are: to consider omitting SBx in serial MRI-negative men at
1-year AS, and to perform both SBx and TBx in serial MRI-
positive men. Previous studies have also investigated the value
of serial MRI and TBx in monitoring men on AS for low-risk
PCa. With respect to the applied AS protocol (i.e., the time
interval between follow-up testing), the studies of Thurtle
et al. [19], Elkjaer et al. [20] and Hamoen et al. [18] are
similar to our present study. Our present results of overall
upgrading (32%) and added value of repeat SBx in MRI-
positive (33%) and MRI-negative men (10%) at 1-year
surveillance of low-risk PCa are mostly in line with the
Table 1 Patients’ characteristics at baseline and at 1-year confirmatory biopsy.
Characteristic Baseline Confirmatory biopsy (1-year surveillance) P*
Total cohort (n = 111) Total cohort (n = 111)
Median (IQR)
Age, years 66 (60–70) 67 (61–71) <0.001
PSA level, ng/mL 6.8 (5.1–9.1) 6.9 (5.2–9.4) 0.352
Prostate volume, mL 42 (30–56) 41 (31–55) 0.695
PSA density, ng/mL/mL 0.17 (0.11–0.25) 0.15 (0.12–0.27) 0.864
N (%)
Clinical stage
T1c 85 (77) 80 (72) 0.665
T2a 22 (20) 25 (23)
T2b 2 (2) 4 (4)
T2c 1 (1) 2 (2)
T3a 1 (1) 0 (0)
TRUS findings
Benign 93 (84) 91 (82) 0.774
Suspected 18 (16) 20 (18)
Number of positive diagnostic cores
1 46 (41) N/A N/A
2 36 (32) N/A
3 19 (17) N/A
4 7 (6) N/A
5 2 (2) N/A
6 1 (1) N/A
PI-RADS score of MRI
1–2 52 (47) 48 (43) 0.303
3 15 (14) 13 (12)
4 35 (32) 40 (36)
5 9 (8) 10 (9)
PRECISE score of MRI
1–2 N/A 14 (13) N/A
3 N/A 80 (72)
4–5 N/A 17 (15)
Time between MRIs, months, median (IQR) N/A 10 (9–13) N/A
Overall ISUP Grade at biopsy, n (%)
No PCa N/A 31 (28) N/A
G 1 111 (100) 45 (41)
G 2 N/A 18 (16)
G 2 with CR and/or IDC N/A 12 (11)
G 3 N/A 5 (5)
G 4–5 N/A 0 (0)
CR, cribriform growth pattern; G, grade; IDC, intraductal carcinoma; ISUP, International Society of Urological Pathology; IQR, interquartile range; N/A, not applicable; PCa,
prostate cancer; PI-RADS, Prostate Imaging-Reporting and Data System; PRECISE, Prostate Cancer Radiological Estimation of Change in Sequential Evaluation. *P values
calculated based on the comparison between the baseline and confirmatory characteristics for the total cohort.
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results of Hamoen et al. [18] (25% overall upgrading and an
added value of repeat SBx in serial MRI-positive men of 36%,
while in MRI-negative men of 50%). The difference in added
value of SBx in MRI-negative men is probably caused by the
fact that in our present study 48 (43%) men had a negative
MRI and repeat SBx, while only eight (11%) men in the
Hamoen et al. [18] cohort had a negative MRI and SBx. Our
present overall percentage of upgrading is also consistent with
the stable 25% re-classification found at each repeat SBx in
the entire PRIAS study (without the use of MRI) [2]. This
finding confirms the high value of re-sampling the prostate
with SBx in men at 1-year AS, which after upfront risk
stratification with MRI appears to have the most added value
in MRI-positive men.
Thurtle et al. [19] and Elkjaer et al. [20] showed, however, a
lower overall upgrading (14–16%) at confirmatory biopsy in
their cohorts and less added value of repeat SBx (12–18%
added value of repeat SBx in serial MRI-positive men and 5–
7% in MRI-negative men). These differences to our present
study could be explained by our daily clinical practice AS
cohort of men with low-risk PCa as opposed to the men with
very low-risk PCa included in their studies. Furthermore, in
the Hamoen et al. [18] study and in our present study, the
repeat SBx was not taken blinded from the MRI results,
which could beneficially influence the SBx outcomes.
Consistent with the upgrading results in other studies, most
men, if upgraded, were upgraded from ISUP Grade 1 to
Grade 2 PCa in our present cohort. This is probably
(partially) caused by previous sampling error, as low-risk PCa
profiles remained equal. This confirms the finding that most
men following an AS programme rarely have high-risk
disease (ISUP Grade ≥3 PCa) during follow-up and therefore
have a good cancer-specific survival [1,28].
Our present results indicate performing SBx in combination
with TBx in all MRI-positive men at 1-year of AS, and also
when there is no radiological progression, which is in line
with the recommendations from Hsiang et al. [23] and
Chesnut et al. [24]. In the total cohort, we detected more
upgrading in men with a PRECISE score 4–5 (41%)
compared to men with a PRECISE score 1–3 (30%) on
follow-up MRI. This finding is consistent with Dieffenbacher
et al. [21], who studied the impact of serial MRIs in AS using
the PRECISE score at 4-years follow-up. However, they
showed a much better discrimination of the PRECISE scoring
system for AS disqualification, with only 10% upgrading
detected in men with a PRECISE score 1–3. Differences
might be explained by the fact that we analysed a cohort at
1-year of AS with substantial added value of repeat prostate
sampling with SBx, while they analysed a cohort at the time
of the third follow-up SBx (4-years after initial diagnosis).
This has probably resulted in an improved patient selection
for AS, with only limited added value of repeat sampling of
Ta
b
le
2
U
p
g
ra
d
in
g
in
M
RI
-p
o
si
tiv
e
a
n
d
-n
e
g
a
tiv
e
m
e
n
p
e
r
d
e
fi
n
iti
o
n
fo
r
c
sP
C
a
a
t
1-
ye
a
r
su
rv
e
ill
a
n
c
e
.
D
e
fi
ni
tio
n
I
D
e
fi
ni
tio
n
II
D
e
fi
ni
tio
n
II
I
Fo
llo
w
-u
p
M
R
I
a
t
1-
ye
a
r
su
rv
e
ill
a
nc
e
N
o
up
g
ra
d
in
g
U
p
g
ra
d
in
g
N
o
up
g
ra
d
in
g
U
p
g
ra
d
in
g
N
o
up
g
ra
d
in
g
U
p
g
ra
d
in
g
N
(%
o
f
to
ta
l)
O
ve
ra
ll,
n
(%
)
O
ve
ra
ll,
n
(%
)
B
io
p
sy
te
c
hn
iq
ue
,
n
(%
o
f
o
ve
ra
ll)
o
r
n/
N
O
ve
ra
ll,
n
(%
)
O
ve
ra
ll,
n
(%
)
B
io
p
sy
te
c
hn
iq
ue
,
n
(%
o
f
o
ve
ra
ll)
o
r
n/
N
O
ve
ra
ll,
n
(%
)
O
ve
ra
ll,
n
(%
)
B
io
p
sy
te
c
hn
iq
ue
,
n
(%
o
f
o
ve
ra
ll)
A
ll
b
io
p
sy
TB
x
+
SB
x
SB
x
o
nl
y
TB
x
o
nl
y
A
ll
b
io
p
sy
TB
x
+
SB
x
SB
x
o
nl
y
TB
x
o
nl
y
A
ll
b
io
p
sy
TB
x
+
SB
x
SB
x
o
nl
y
TB
x
o
nl
y
T
ot
al
11
1
(1
00
)
76
(6
8)
35
(3
2)
13
(3
7)
15
(4
3)
7
(2
0)
94
(8
5)
17
(1
5)
4
(2
4)
10
(5
9)
3
(1
8)
10
6
(9
5)
5
(5
)
1/
5
3/
5
1/
5
P
os
it
iv
e
M
R
I
P
I-
R
A
D
S
3–
5
63
(5
7)
33
(5
2)
30
(4
8)
13
(4
3)
10
(3
3)
7
(2
3)
49
(7
8)
14
(2
2)
4/
14
7/
14
3/
14
59
(9
4)
4
(6
)
1/
4
2/
4
1/
4
N
eg
at
iv
e
M
R
I
P
I-
R
A
D
S
1–
2
48
(4
3)
43
(9
0)
5
(1
0)
x
5/
5
x
45
(9
4)
3
(6
)
x
3/
3
x
47
(9
8)
1
(2
)
x
1/
1
x
PI
-R
A
D
S,
Pr
os
ta
te
Im
ag
in
g-
R
ep
or
ti
ng
an
d
D
at
a
Sy
st
em
;
SB
x,
sy
st
em
at
ic
bi
op
sy
;
T
B
x,
ta
rg
et
ed
bi
op
sy
.
6
© 2020The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Osses et al.
the whole prostate at the time of their analysis. In addition,
the fact remains that the assessment of serial MRIs in men
on AS is challenging, as upgrading still occurs with some
regularity in men with an apparent stable low-risk disease on
positive MRI due to the high value of repeat prostate
sampling. Therefore, serial MRIs and the PRECISE criteria
need to be investigated more often in clinical AS cohorts of
men with low-risk PCa to help with the creation of a robust
dataset to define proper radiological thresholds of csPCa in
men on AS.
The present study is the first to investigate the role of serial
prostate MRIs in a daily clinical practice of AS (following a
strict protocol) related to the presence of CR and IDC in
biopsy specimens. CR and IDC are prognostic drivers in
survival, even more than other Gleason 4 subpatterns [29].
Kweldam et al. [30] showed that men with ISUP Grade 2
PCa with the presence of CR/IDC were associated with a
worse disease-specific survival (67%) at 15-years follow-up,
compared to men with ISUP Grade 2 PCa without the
presence of CR/IDC (94%) and men with Grade 1 PCa
(99%). Identifying these Gleason 4 patterns in men on AS
may therefore be of high clinical relevance, with subsequently
a large population staying on AS without CR/IDC. In our
present population, overall upgrading defined by ISUP Grade
≥2 with CR and/or IDC PCa (definition II) decreased from
32% to 15%, potentially saving even more biopsy procedures
(e.g., in PI-RADS score 3 men) and keeping more men on
AS. Incorporation of this tumour-specific information into
risk stratification could further improve selection of men who
will benefit from active treatment. We may argue that the
threshold for upgrading in men on AS should be changed to
ISUP Grade ≥2 with CR and/or IDC PCa, to (falsely) exclude
less men from AS and thereby to reduce the rate of
overtreatment and treatment-related side-effects.
Some limitations of our present study should be highlighted.
First, our study has a retrospective design and could thereby
introduce a selection bias. However, our study represents a
prospective cohort of consecutive men on AS with strict
monitoring. Second, clinicians involved were not blinded to
clinical data and MRI results. Hence, this process is daily
clinical practice and therefore can be extrapolated to other
hospitals. Third, the sample size of our study is relatively
small, which could reduce generalisability. However, in
comparison to similar studies in the recent literature, it is the
second largest sample size available in a study on the use of
serial MRI in men on AS at 1-year surveillance for low-risk
PCa. Lastly, the median follow-up time was limited to
33 months. We acknowledge that the outcome measurement
of our analysis was upgrading at 1-year surveillance. The
cancer-specific survival rate in a long-term follow-up would
have been more appropriate to make hard inferences about the
need for and frequencies of surveillance testing. This outcome
may, however, be debatable in a cohort of men with low-riskTa
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disease who exhibit excellent long-term cancer-specific survival
and who furthermore experience most shifts from AS to active
treatment during the first 2 years of follow-up [31].
In conclusion, at 1-year surveillance the performance of
repeat SBx in serial MRI-negative men should be discussed
per individual based on one’s balance between benefits (e.g.
not missing any intermediate/high-risk disease) and harms
(e.g. unnecessary biopsy, biopsy complications). In serial
MRI-positive men, repeat SBx should be performed together
with MRI-TBx in all MRI-positive men, and also when there
is no radiological progression. These findings are irrespective
of upgrading threshold. Future large-scale studies should
confirm this and focus on other surveillance issues in the
current MRI era, such as the need for, the intervals, and
frequencies of surveillance testing from 2 years after the
diagnosis of low-risk PCa.
Conflicts of Interest
The authors declare no conflict of interest.
References
1 Klotz L, Vesprini D, Sethukavalan P et al. Long-term follow-up of a
large active surveillance cohort of patients with prostate cancer. J Clin
Oncol 2015; 33: 272–7
2 Bokhorst LP, Valdagni R, Rannikko A et al. A decade of active
surveillance in the PRIAS study: an update and evaluation of the criteria
used to recommend a switch to active treatment. Eur Urol 2016; 70: 954–
60
3 Schoots IG, Moore CM, Rouviere O. Role of MRI in low-risk prostate
cancer: finding the wolf in sheep’s clothing or the sheep in wolf’s
clothing? Curr Opin Urol 2017; 27: 238–45
4 Marliere F, Puech P, Benkirane A et al. The role of MRI-targeted and
confirmatory biopsies for cancer upstaging at selection in patients
considered for active surveillance for clinically low-risk prostate cancer.
World J Urol 2014; 32: 951–8
5 Ouzzane A, Renard-Penna R, Marliere F et al. Magnetic resonance
imaging targeted biopsy improves selection of patients considered for
active surveillance for clinically low risk prostate cancer based on
systematic biopsies. J Urol 2015; 194: 350–6
6 Abdi H, Pourmalek F, Zargar H et al. Multiparametric magnetic
resonance imaging enhances detection of significant tumor in patients on
active surveillance for prostate cancer. Urology 2015; 85: 423–8
7 Recabal P, Ehdaie B. The role of MRI in active surveillance for men with
localized prostate cancer. Curr Opin Urol 2015; 25: 504–9
8 Alberts AR, Roobol MJ, Drost FH et al. Risk-stratification based on
magnetic resonance imaging and prostate-specific antigen density may
reduce unnecessary follow-up biopsy procedures in men on active
surveillance for low-risk prostate cancer. BJU Int 2017; 120: 511–9
9 Schoots IG, Osses DF, Drost FH et al. Reduction of MRI-targeted
biopsies in men with low-risk prostate cancer on active surveillance by
stratifying to PI-RADS and PSA-density, with different thresholds for
significant disease. Transl Androl Urol 2018; 7: 132–44
10 Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG guidelines on
prostate cancer. Part 1: screening, diagnosis, and local treatment with
curative intent. Eur Urol 2019; 71: 618–29
11 Moore CM, Giganti F, Albertsen P et al. Reporting magnetic resonance
imaging in men on active surveillance for prostate cancer: the PRECISE
Recommendations-A Report of a European School of Oncology Task
Force. Eur Urol 2017; 71: 648–55
12 Giganti F, Allen C, Piper JW et al. Sequential prostate MRI reporting in
men on active surveillance: initial experience of a dedicated PRECISE
software program. Magn Reson Imaging 2019; 57: 34–9
13 Walton Diaz A, Shakir NA, George AK et al. Use of serial
multiparametric magnetic resonance imaging in the management of
patients with prostate cancer on active surveillance. Urol Oncol 2015; 33:
202.e1–7
14 Felker ER, Wu J, Natarajan S et al. Serial magnetic resonance imaging in
active surveillance of prostate cancer: incremental value. J Urol 2016; 195:
1421–7
15 Eineluoto JT, Jarvinen P, Kenttamies A et al. Repeat multiparametric
MRI in prostate cancer patients on active surveillance. PLoS ONE 2017;
12: e0189272. DOI: 10.1371/journal.pone.0189272.
16 Olivier J, Kasivisvanathan V, Drumez E et al. Low-risk prostate cancer
selected for active surveillance with negative MRI at entry: can repeat
biopsies at 1 year be avoided? A pilot study. World J Urol 2018; 37: 253–9
17 Gallagher KM, Christopher E, Cameron AJ et al. Four-year outcomes
from a multiparametric magnetic resonance imaging (MRI)-based active
surveillance programme: PSA dynamics and serial MRI scans allow
omission of protocol biopsies. BJU Int 2018; 123: 429–38.
18 Hamoen EH, Hoeks CM, Somford DM et al. Value of serial
multiparametric magnetic resonance imaging and magnetic resonance
imaging-guided biopsies in men with low-risk prostate cancer on active
surveillance after 1 yr follow-up. Eur Urol Focus 2019; 5: 407–15.
19 Thurtle D, Barrett T, Thankappan-Nair V et al. Progression and
treatment rates using an active surveillance protocol incorporating image-
guided baseline biopsies and multiparametric magnetic resonance imaging
monitoring for men with favourable-risk prostate cancer. BJU Int 2018;
122: 59–65
20 Elkjaer MC, Andersen MH, Hoyer S, Pedersen BG, Borre M. Multi-
parametric magnetic resonance imaging monitoring patients in active
surveillance for prostate cancer: a prospective cohort study. Scand J Urol.
2018; 52: 8–13
21 Dieffenbacher S, Nyarangi-Dix J, Giganti F et al. Standardized magnetic
resonance imaging reporting using the prostate cancer radiological
estimation of change in sequential evaluation criteria and magnetic
resonance imaging/transrectal ultrasound fusion with transperineal
saturation biopsy to select men on active surveillance. Eur Urol Focus
2019 [Epub ahead of print]. https://doi.org/10.1016/j.euf.2019.03.001
22 Klotz L, Pond G, Loblaw A et al. Randomized study of systematic biopsy
versus magnetic resonance imaging and targeted and systematic biopsy in
men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol
2020; 77: 311–7
23 Hsiang W, Ghabili K, Syed JS et al. Outcomes of serial multiparametric
magnetic resonance imaging and subsequent biopsy in men with low-risk
prostate cancer managed with active surveillance. Eur Urol Focus 2019
[Epub ahead of print]. https://doi.org/10.1016/j.euf.2019.05.011.
24 Chesnut GT, Vertosick EA, Benfante N et al. Role of changes in
magnetic resonance imaging or clinical stage in evaluation of disease
progression for men with prostate cancer on active surveillance. Eur Urol
2020; 77: 501–7
25 Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS prostate imaging –
reporting and data system: 2015, version 2. Eur Urol 2016; 69: 16–40
26 Epstein JI, Egevad L, Amin MB et al. The 2014 International Society of
Urological Pathology (ISUP) consensus conference on Gleason grading of
prostatic carcinoma: definition of grading patterns and proposal for a new
grading system. Am J Surg Pathol 2016; 40: 244–52
27 Moore CM, Kasivisvanathan V, Eggener S et al. Standards of reporting
for MRI-targeted biopsy studies (START) of the prostate:
recommendations from an International Working Group. Eur Urol 2013;
64: 544–52
8
© 2020The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Osses et al.
28 Hamdy FC, Donovan JL, Lane JA et al. 10-year outcomes after
monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl
J Med 2016; 375: 1415–24
29 Zlotta AR, Egawa S, Pushkar D et al. Prevalence of prostate cancer on
autopsy: cross-sectional study on unscreened Caucasian and Asian men. J
Natl Cancer Inst 2013; 105: 1050–8
30 Kweldam CF, K€ummerlin IP, Nieboer D et al. Disease-specific survival
of patients with invasive cribriform and intraductal prostate cancer at
diagnostic biopsy. Modern Pathol 2016; 29: 630–6
31 Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical
prostatectomy findings in patients in whom active surveillance of prostate
cancer fails. J Urol 2009; 182: 2274–8
Correspondence: Dani€el F. Osses, Department of Radiology &
Nuclear Medicine, Erasmus University Medical Center;
Department of Urology, Erasmus University Medical Center,
Doctor Molewaterplein 40, 3015 GD Rotterdam, The
Netherlands.
e-mail: d.osses@erasmusmc.nl
Abbreviations: AS, active surveillance; CR, cribriform growth
pattern; csPCa, clinically significant prostate cancer; EAU,
European Association of Urology; IDC, intraductal
carcinoma; IQR, interquartile range; IRB, Institutional Review
Board; ISUP, International Society of Urological Pathology;
mpMRI, multiparametric MRI; MRI  TBx, MRI with or
without TBx; PCa, prostate cancer; PI-RADS, Prostate
Imaging Reporting and Data System; PRECISE, Prostate
Cancer Radiological Estimation of Change in Sequential
Evaluation; PRIAS, Prostate cancer Research International
Active Surveillance; SBx, systematic TRUS-guided prostate
biopsy; START, Standards of reporting for MRI-targeted
biopsy studies; TBx, targeted biopsy.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Cross-tabulation of serial MRI with or without
targeted biopsy results vs repeat systematic biopsy results, at
1-year surveillance. MRI, magnetic resonance imaging; TBx,
targeted biopsy; ISUP, International Society of Urological
Pathology; PI-RADS, Prostate Imaging Reporting and Data
System; TBx, targeted biopsy; SBx, systematic biopsy; PCa,
prostate cancer; G, grade; CR, cribriform growth pattern;
IDC, intraductal carcinoma.
© 2020The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 9
Serial MRI and repeat biopsy in men on AS
